JP2012510813A - 卵巣癌の診断および治療のためのマイクロｒｎａに基づく方法および組成物 - Google Patents

卵巣癌の診断および治療のためのマイクロｒｎａに基づく方法および組成物 Download PDF

Info

Publication number
JP2012510813A
JP2012510813A JP2011539528A JP2011539528A JP2012510813A JP 2012510813 A JP2012510813 A JP 2012510813A JP 2011539528 A JP2011539528 A JP 2011539528A JP 2011539528 A JP2011539528 A JP 2011539528A JP 2012510813 A JP2012510813 A JP 2012510813A
Authority
JP
Japan
Prior art keywords
mir
biomarker
subject
ovarian cancer
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011539528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012510813A5 (https=
Inventor
コーン，ディヴィッド・イー
レスニック，キンバリー
アルダー，ハンスユルグ
クロース，カーロ・エム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Publication of JP2012510813A publication Critical patent/JP2012510813A/ja
Publication of JP2012510813A5 publication Critical patent/JP2012510813A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/207—Modifications characterised by siRNA, miRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011539528A 2008-12-05 2009-03-25 卵巣癌の診断および治療のためのマイクロｒｎａに基づく方法および組成物 Pending JP2012510813A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12012308P 2008-12-05 2008-12-05
US61/120,123 2008-12-05
PCT/US2009/038214 WO2010065156A1 (en) 2008-12-05 2009-03-25 Microrna-based methods and compositions for the diagnosis and treatment of ovarian cancer

Publications (2)

Publication Number Publication Date
JP2012510813A true JP2012510813A (ja) 2012-05-17
JP2012510813A5 JP2012510813A5 (https=) 2013-05-09

Family

ID=42233538

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011539528A Pending JP2012510813A (ja) 2008-12-05 2009-03-25 卵巣癌の診断および治療のためのマイクロｒｎａに基づく方法および組成物

Country Status (7)

Country Link
US (3) US20110275534A1 (https=)
EP (1) EP2373815A4 (https=)
JP (1) JP2012510813A (https=)
CN (1) CN102292456A (https=)
AU (2) AU2009322907B2 (https=)
CA (1) CA2745746A1 (https=)
WO (1) WO2010065156A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101784714B1 (ko) 2014-08-19 2017-10-12 주식회사 엠모니터 재발 난소암 진단 또는 난소암 재발 예측용 mirna 마커 및 그 용도

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5489459B2 (ja) 2005-08-01 2014-05-14 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 乳癌の診断、予後及び治療のためのマイクロｒｎａに基づいた方法及び組成物
CA2845251A1 (en) 2005-09-12 2007-03-22 The Ohio State University Research Foundation Compositions for the therapy of bcl2-associated cancers and methods of preparation thereof
CN102943108B (zh) 2006-01-05 2014-05-21 俄亥俄州立大学研究基金会 用于肺癌的诊断、预后和治疗的基于微小rna的方法和组合物
EP2487258B1 (en) 2006-01-05 2014-10-01 The Ohio State University Research Foundation MicroRNA-based methods for the diagnosis of colon, pancreas and stomach cancer
JP5490413B2 (ja) 2006-01-05 2014-05-14 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 膵内分泌腫瘍及び膵腺房腫瘍におけるマイクロｒｎａ発現異常
ES2446362T3 (es) 2006-03-20 2014-03-07 The Ohio State University Research Foundation Huellas de microARN durante megacariocipoyesis humana
CA2657030A1 (en) 2006-07-13 2008-01-17 The Ohio State University Research Foundation, An Instrumentality Of The State Of Ohio Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
CN101535505A (zh) 2006-09-19 2009-09-16 俄亥俄州立大学研究基金会 慢性淋巴细胞性白血病(CLL)中受miR-29和miR-181调控的TCL1的表达
EP2087135B8 (en) 2006-11-01 2013-07-24 The Ohio State University Research Foundation Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma
CN105256004A (zh) 2007-01-31 2016-01-20 俄亥俄州立大学研究基金会 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物
ES2527648T3 (es) 2007-06-08 2015-01-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Métodos para determinar el subtipo de carcinoma hepatocelular
EP2719773A3 (en) 2007-06-15 2014-07-30 The Ohio State University Research Foundation miRNA as marker for acute lamphomic leucemia
ES2496172T3 (es) 2007-07-31 2014-09-18 The Ohio State University Research Foundation Métodos para invertir la metilación por selección dirigida de DNMT3A y DNMT3B
JP2010535473A (ja) 2007-08-03 2010-11-25 ズィ、オハイオウ、ステイト、ユーニヴァーサティ、リサーチ、ファウンデイシャン ｎｃＲＮＡをコードする超保存領域
CA2696887C (en) 2007-08-22 2016-06-28 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
CN102137927B (zh) 2007-10-26 2014-03-12 俄亥俄州立大学研究基金会 鉴定脆性组氨酸三联体(Fhit)相互作用的方法及其用途
WO2009108853A1 (en) * 2008-02-28 2009-09-03 The Ohio State University Research Foundation MicroRNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF GASTRIC CANCER
ES2433940T3 (es) 2008-06-11 2013-12-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Uso de la familia miR-26 como marcador predictivo del carcinoma hepatocelular y sensibilidad a la terapia
US8916533B2 (en) 2009-11-23 2014-12-23 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
AU2011219029B2 (en) * 2010-02-26 2017-02-02 Columbia University Methods and compositions for the detection and treatment of cancer involving miRNAs and miRNA inhibitors and targets
JP5931897B2 (ja) 2010-11-12 2016-06-08 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションＴｈｅ Ｏｈｉｏ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ マイクロｒｎａ−２１、ミスマッチ修復および結腸直腸癌に関連する物質および方法
CA2817982C (en) 2010-11-15 2020-06-30 The Regents Of The University Of Michigan Controlled release mucoadhesive systems
WO2012122239A1 (en) 2011-03-07 2012-09-13 The Ohio State University MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (miR-155) LINKS INFLAMMATION AND CANCER
WO2012135814A2 (en) * 2011-03-31 2012-10-04 University Of Houston Microrna29a,b,c as a tumor suppressor and sensitizing agent for chemotherapy
AU2012323924A1 (en) * 2011-10-14 2014-05-29 The Ohio State University Methods and materials related to ovarian cancer
CA2859430A1 (en) * 2011-12-13 2013-06-20 Ohio State Innovation Foundation Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis
US8859202B2 (en) 2012-01-20 2014-10-14 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
WO2014071226A1 (en) 2012-11-02 2014-05-08 The Regents Of The University Of California Methods and systems for determining a likelihood of adverse prostate cancer pathology
CN104123480B (zh) * 2013-04-27 2017-03-08 中国科学院上海生命科学研究院 新型微rna筛选方法、验证系统及其应用
KR101508580B1 (ko) 2013-05-14 2015-04-07 연세대학교 산학협력단 재발성 난소암의 예측 또는 진단 방법
CN103952465A (zh) * 2013-12-10 2014-07-30 长沙赢润生物技术有限公司 一种基于血浆microRNA分析的卵巢癌肿瘤诊断方法
CN108348547B (zh) * 2015-08-28 2023-09-22 纽约市哥伦比亚大学信托人 用于匹配肿瘤学特征的系统和方法
EP3147370A1 (en) * 2015-09-28 2017-03-29 Rheinische Friedrich-Wilhelms-Universität Bonn Exosomal microrna in serum as an indicator for the activation of brown and beige fat tissue (bat)
CN105177173A (zh) * 2015-11-02 2015-12-23 崔长友 用于卵巢癌诊断的miRNA生物标志物及检测试剂盒
JP7130562B2 (ja) 2016-03-17 2022-09-05 ベクトン・ディキンソン・アンド・カンパニー ハイスループット蛍光フローサイトメーターを用いる細胞選別
CN105695612A (zh) * 2016-04-19 2016-06-22 中南大学 microRNA-126-5p在心肌损伤中的表达检测方法
CN106520924A (zh) * 2016-10-14 2017-03-22 浙江大学 一种用于检测卵巢癌的引物组及检测方法
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
EP3565903A4 (en) * 2017-01-09 2020-12-23 Dana-Farber Cancer Institute, Inc. CIRCULATING MICRORNA SIGNATURES FOR OVARIAN CANCER
EP3681895A4 (en) 2017-09-13 2021-05-26 Becton, Dickinson and Company METHODS AND COMPOSITIONS FOR EXTRACTION OF NUCLEIC ACIDS USING FERROUS PARTICLES
US12291750B2 (en) * 2018-07-05 2025-05-06 Universite De Caen Normandie Predictive and prognostic use of a miRNA for high grade serous ovarian carcinoma therapeutic care
KR20210137828A (ko) * 2020-05-11 2021-11-18 의료법인 성광의료재단 기계학습 예측모델을 이용한 난소암 진단 방법 및 이를 적용하는 시스템
WO2021262919A2 (en) 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
CN112626209A (zh) * 2020-12-22 2021-04-09 绵竹市人民医院 用于卵巢癌诊断的miRNA标志物、其应用及诊断试剂盒

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050182005A1 (en) * 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
JP5489459B2 (ja) * 2005-08-01 2014-05-14 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 乳癌の診断、予後及び治療のためのマイクロｒｎａに基づいた方法及び組成物
EP2487258B1 (en) * 2006-01-05 2014-10-01 The Ohio State University Research Foundation MicroRNA-based methods for the diagnosis of colon, pancreas and stomach cancer
US9115389B2 (en) * 2006-06-30 2015-08-25 Rosetta Genomics Ltd. Method for detecting a target nucleic acid comprising two portions using probes having a first portion complementary to the first portion of the target nucleic acid and a second portion substantially complementary to the second portion of the target nucleic acid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013052933; Ｇｙｎｅｃｏｌ．　Ｏｎｃｏｌ．，　（２００８．０７），　１１０，　［１］，　ｐ．１３-２１ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101784714B1 (ko) 2014-08-19 2017-10-12 주식회사 엠모니터 재발 난소암 진단 또는 난소암 재발 예측용 mirna 마커 및 그 용도

Also Published As

Publication number Publication date
WO2010065156A1 (en) 2010-06-10
US20170037412A1 (en) 2017-02-09
EP2373815A4 (en) 2012-09-26
US20140256591A1 (en) 2014-09-11
CN102292456A (zh) 2011-12-21
CA2745746A1 (en) 2010-06-10
US20110275534A1 (en) 2011-11-10
AU2016204376A1 (en) 2016-07-14
AU2009322907A1 (en) 2011-07-28
EP2373815A1 (en) 2011-10-12
AU2009322907B2 (en) 2016-05-05
US9499869B2 (en) 2016-11-22

Similar Documents

Publication Publication Date Title
US9499869B2 (en) MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of ovarian cancer using a real-time PCR platform
EP2799557B1 (en) MiR-32 antagonists for increasing responsiveness of prostate cancer to apoptosis
JP5230619B2 (ja) 結腸癌関連疾患の診断及び治療のためのマイクロｒｎａに基づいた方法及び組成物
EP2257647B1 (en) Micro rna-based methods and compositions for the diagnosis of gastric cancer
US20120283310A1 (en) MicroRNA Signatures Associated with Human Chronic Lymphocytic Leukemia (CLL) and Uses Thereof
US20110021609A1 (en) MicroRNA Signatures Associated with Cytogenetics and Prognosis in Acute Myeloid Leukemia (AML) and Uses Thereof
EP3122905B1 (en) Circulating micrornas as biomarkers for endometriosis
EP3144395A1 (en) Microrna signature as an indicator of the risk of early recurrence in patients with breast cancer
EP1620565A2 (en) Method for detection and characterization of pre-malignant transformation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131025

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140320